BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:BBIO) PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”). The committee approved: (i) on September 5, 2025, RSU grants covering an aggregate of 33,684 shares of the Company’s common stock to 13 new employees; (ii) on August 4, 2025, RSU grants covering an aggregate of 32,145 shares of the Company’s common stock to 16 new employees; and (iii) on July 14, 2025, RSU grants covering an aggregate of 73,991 shares of the Company’s common stock to 20 new employees. One-fourth of the shares underlying these RSUs will vest on August 16, 2026, with the remaining shares vesting in equal quarterly installm